Clinical Research Progress of Tirzepatide: a New Hypoglycemic Agent

Abstract

Despite the availability of various drugs for the treatment of diabetes worldwide, many patients still fail to achieve the recommended target blood sugar levels. Therefore, it is urgent to develop and apply new hypoglycemic drugs. In May 2022, FDA approved tirzepatide, a dual receptor agonist for GIP and GLP-1, administrated once a week to improve blood glucose control in adults with type 2 diabetes by assisting diet and exercise. Numerous clinical studies have proven its effectiveness and safety in type 2 diabetes, and its potential applications in obesity, cardiovascular diseases, non-alcoholic steatohepatitis and so on. In this paper, the mechanism of action, efficacy and safety of tirzepatide were reviewed to provide a reference for its clinical application after marketed in China.

Keywords

• diabetes mellitus, type 2|hypoglycemic agents|tirzepatide|glucose-dependent insulinotropic polypeptide /glucagon-like peptide-1 receptor agonist|obesity|effectiveness|safety|review